Clinical trials: Overweight, Obesity
Type 2 Diabetes
Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar
The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM.
- Trial name
- NCT04081064
- Testing
- 10-week exercise programme based on aerobic interval and resistance training
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Obesity, Diabetes
Gelesis Glycemic Index Study
A study to determine glucose and insulin responses to 50g and 100 g of carbohydrate with and without Gelesis200.
- Conditions
- Obesity, Diabetes, PreDiabetes
- Trial name
- GLIDE (NCT03124134)
- Testing
- Gelesis200
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gelesis, Inc.
Prader-Willi Syndrome
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
- Trial name
- NCT07450664
- Testing
- VYKAT XR
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Soleno Therapeutics, Inc.
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity
NNC0487-0111 is a new medicine similar to 2 hormones that are produced in human body: amylin and glucagon-like peptide-1 (GLP-1). Both hormones work like body's own hormones and help the body to feel full.
- Trial name
- NCT05369390
- Testing
- NNC0487-0111 A, NNC0487-0111 B
- Where
- 2 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Metabolic Factors of Outcomes From Gastric Bypass Surgery
The objective of this study is to determine whether the metabolic, endocrine and energetic response to short term caloric restriction are factors in weight loss in subjects having gastric bypass (GB) surgery.
- Trial name
- Cassini (NCT01347840)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ethicon Endo-Surgery
Healthy, Obesity
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study.
- Trial name
- NCT05751226
- Testing
- BI 1820237, semaglutide, BI 456906
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Effect of Shock Wave Therapy Without Biological and Immuno-histochemical Analysis.
Informative Summary: Extracorporeal shockwave therapy (ESWT) is a new method for treating aesthetic disorders within the field of aesthetic medicine, its mechanisms of action and physiological effects promise to combat localized…
- Trial name
- ESWT (NCT05017636)
- Testing
- shock wave therapy
- Where
- Brazil
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Indústria Brasileira Equipamentos Médicos - IBRAMED
Obesity
A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
MOD-6031 is a long-acting reversibly PEGylated oxyntomodulin (OXM) therapeutic. The active moiety is a gastrointestinal neuropeptide with a sequence identical to endogenous human OXM and is an agonist for both glucagon-like…
- Trial name
- NCT02692781
- Testing
- MOD-6031
- Where
- Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Type 2 Diabetes Mellitus
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00404963
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight, Obesity
Effect of Soy Protein and Colorado Diet on Weight Loss and Maintenance
Dietary protein is a key element of most effective weight loss regimens. This study will investigate the effects of consuming soy protein on body composition and cardiometabolic health within the context of an effective weight…
- Conditions
- Overweight, Obesity, Weight Loss
- Trial name
- NCT02380963
- Testing
- Colorado Diet with soy protein foods., Colorado Diet with monetary payments
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- DuPont Nutrition and Health
Obesity &Amp; Overweight
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite…
- Trial name
- NCT07056842
- Testing
- Rifampin + VCT220, Itraconazole + VCT220
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Type2diabetes
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in…
- Trial name
- DehydraTECH (NCT06648031)
- Testing
- Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
- Where
- 7 sites in Australia
- Volunteers
- 148 people
- Sponsor
- Lexaria Bioscience Corp.
Obesity, Cardiovascular Diseases
Naltrexone/Bupropion Cardiovascular Outcomes Study
The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse…
- Trial name
- NCT02638129
- Testing
- Naltrexone HCl/Bupropion HCl ER
- Where
- 139 sites in United States
- Volunteers
- 67 people
- Sponsor
- Orexigen Therapeutics, Inc
Prader-Willi Syndrome
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
The purpose of this study was to evaluate the effects of a once daily subcutaneous injectable formulation of setmelanotide in obese participants with Prader-Willi syndrome on tolerability, weight loss, and hyperphagia-related…
- Trial name
- NCT02311673
- Testing
- Setmelanotide
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part…
- Trial name
- NCT06700538
- Testing
- ARO-INHBE, Tirzepatide
- Where
- 15 sites in Australia, Canada and 2 more
- Volunteers
- 190 people
- Sponsor
- Arrowhead Pharmaceuticals
Typ 2 Diabetes, Obesity
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
Approval study Trans-Duodenal Barrier The goal of this clinical trial is to determin the safety and performance of the newly developed Trans-Duodenal Barrier in adult Tryp 2 diabetic and obese patients.
- Conditions
- Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
- Trial name
- LuST (NCT07417683)
- Testing
- endoscopic implant
- Where
- 8 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Trans-Duodenal Concepts GmbH
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
Gastric On in Obesity Management: Evaluation of the Safety and Efficacy of the 6-Month Gastric Balloon (Prospective)
The goal of this clinical study is to learn whether the GastricOn 6-Month Gastric Balloon helps adults with obesity lose weight, and how safe it is.
- Trial name
- GastricOn (NCT07869758)
- Testing
- GastricOn intragastric balloon
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Rigicon, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.